Analyst Ratings For NASDAQ:IOVA – Iovance Biotherapeutics (NASDAQ:IOVA)
Today, NASDAQ:IOVA – Iovance Biotherapeutics (NASDAQ:IOVA) stock received an upgrade by B. Riley from Neutral to Buy with a price target of $22.00.
Some recent analyst ratings include
- 4/10/2018-B. Riley Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 1/29/2018-Wells Fargo Reiterated Rating of Buy.
- 1/22/2018-Chardan Capital Reiterated Rating of Buy.
- 10/25/2017-FBR & Co Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:IOVA – Iovance Biotherapeutics (NASDAQ:IOVA)
NASDAQ:IOVA – Iovance Biotherapeutics (NASDAQ:IOVA) has insider ownership of 13.20% and institutional ownership of 64.44%.
- On 8/25/2016 Sanford Hillsberg, Director, sold 54,000 with an average share price of $8.95 per share and the total transaction amounting to $483,300.00.
- On 8/22/2016 Sanford Hillsberg, Director, sold 54,000 with an average share price of $9.11 per share and the total transaction amounting to $491,940.00.
- On 9/8/2015 Sanford Hillsberg, Director, sold 32,500 with an average share price of $6.99 per share and the total transaction amounting to $227,175.00.
- On 5/6/2015 Sanford Hillsberg, Director, sold 50,000 with an average share price of $10.00 per share and the total transaction amounting to $500,000.00.
- On 11/5/2013 Manish Singh, CEO, bought 125,000 with an average share price of $2.00 per share and the total transaction amounting to $250,000.00.
Recent Trading Activity for NASDAQ:IOVA – Iovance Biotherapeutics (NASDAQ:IOVA)
Shares of NASDAQ:IOVA – Iovance Biotherapeutics closed the previous trading session at 15.45 up +1.00 6.92% with shares trading hands.